Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories orders, deals and press releases
601 filed, newest first. Page 11 of 13.
May 2011
Apr 2011
Mar 2011
11 Mar · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 18,985 equity shares of Rs. 5/- each of the Company, fully paid up, on March 11, 2011, to Employees on exercise of their Stock Options.
Jan 2011
10 Jan · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 6,440 equity shares of Rs.5/- each of the Company, fully paid up, on January 08, 2011, to Employees on exercise of their Stock Options as per the following details : (1) 5,300 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 1,140 equity shares of Rs.5/- each underlying 1,140 ADRs pursuant to Dr.Reddy's Employees ADR Stock Option Scheme, 2007.
Dec 2010
Nov 2010
1 Nov · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 25,732 equity shares of Rs.5/- each of the Company, fully paid up, on October 30, 2010, to Director/Employees on exercise of their Stock Options as per the following details : (1) 22,472 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 3,260 equity shares of Rs.5/- each underlying 3,260 ADRs pursuant to Dr.Reddy's Employees ADR Stock Option Scheme, 2007.
Oct 2010
Sep 2010
Aug 2010
31 Aug · Business
Dr. Reddy's Laboratories Limited has informed the Exchange that the Governance & Compensation Committee of the Board of Directors of the Company has allotted 57,312 equity shares of Rs. 5/- each of the Company, fully paid up, on August 30, 2010, to Employees on exercise of their Stock Options as per the following details : (1) 53,304 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 4,008 equity shares of Rs.5/- each underlying 4,008 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.
Jul 2010
Jun 2010
29 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Governance & Compensation Committee of the Board of Directors of the Company has allotted the following equity shares of Rs.5/- each of the Company, fully paid up, on June 28, 2010, to Directors / Employees on exercise of their Stock Options : (1) 134,825 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 35,643 equity shares of Rs.5/- each underlying 35,643 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.2 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that pursuant to Dr Reddy's Employees Stock Option Scheme, 2002, the Governance & Compensation Committee of the Board of Directors of the Company has allotted 128,410 equity shares of Rs.5/- each of the Company, fully paid up, on June 1, 2010, to Directors / Employees on exercise of their Stock Options.
May 2010
Apr 2010
26 Apr · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange regarding a press release dated April 26, 2010, titled "Dr.Reddy's announces the Launch of Amlodipine Benazepril in US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 15, 2010, titled "Dr. Reddy's introduces 'Dose Counter Inhalers' for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
17 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 17, 2010, titled "Dr. Reddy's Custom Pharmaceutical Services (CPS) business commissions mPEG alcohol manufacturing facility and officially brands its Activated mPEG Products as PEGtech". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
3 Feb · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated February 03, 2010, titled "Sanjeev Verma appointed as new Head of Corporate Communications and Branding". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
20 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 20, 2010, titled "Dr.Reddy's Q3 FY10 Financial Results- Revenues at Rs. 17,296 million, EBITDA at Rs. 3,666 million, Profits after Tax adjusted for impairment at Rs. 2,307 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 04, 2010, titled "Dr.Reddy's and Rheoscience announce headline results from First Phase III clinical trial of Balaglitazone (DRF 2593)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
23 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 23, 2009, titled "Dr. Reddy's Q2 FY10 Results, Revenues at Rs.18,368 million, up by 14% EBITDA at Rs.3,797 million, up by 51%, PAT at Rs.2,173 million, up by 106%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 20, 2009, titled "Dr. Reddy's joins American Chemicals Society Green Chemistry Institute Pharmaceutical Roundtable". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 06, 2009, titled "Dr. Reddy's launches Strea(TM) C10 and Strea(TM) A15 in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
13 Aug · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated August 13, 2009, titled "Dr. Reddy's launches Strea(TM) Professional in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Aug · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated August 05, 2009, titled "Dr. Reddy's launches FINRID (TM) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
30 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 30, 2009, titled "Dr. Reddy's launches Execare (TM) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 21, 2009, titled "Dr. Reddy's Q1 FY10 Results, Revenues at Rs.18,189 million, up by 21% EBITDA at Rs.4,364 million, up by 90%, PAT at Rs.2,445 million, up by 120%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 07, 2009, titled "Dr. Reddy's Laboratories Limited announces filing of Annual Report on From 20-F". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
23 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 23, 2009, titled "Dr. Reddy's launches Bispec(TM) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 15, 2009, titled "Dr. Reddy's announces strategic alliance with GSK for Emerging Markets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 09, 2009, titled "Dr. Reddy's announces ANDA approval of Omeprazole Mg OTC". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
21 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 21, 2009, titled "Dr. Reddy's receives approval for Three INDs and announces reorganization of its Drug Discovery Operations". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 18, 2009, titled "Dr. Reddy's FY09 Revenues at Rs.69,441 million; EBITDA at Rs.14,505 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
28 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 28, 2009, titled "Dr. Reddy's launches Nexret (TM)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.